We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

22 hedge funds and large institutions have $9.69M invested in SAB Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

2.3% less ownership

Funds ownership: 36.18% → 33.88% (-2.3%)

8% less funds holding

Funds holding: 24 → 22 (-2)

36% less capital invested

Capital invested by funds: $15.2M → $9.69M (-$5.47M)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$367K
2
FPB
First PREMIER Bank
South Dakota
+$71.1K
3
BlackRock
BlackRock
New York
+$27.2K
4
TRCT
Tower Research Capital (TRC)
New York
+$3.51K
5
Bank of America
Bank of America
North Carolina
+$605

Top Sellers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
-$832K
2
RI
RTW Investments
New York
-$553K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$14.9K
4
Millennium Management
Millennium Management
New York
-$4.64K
5
SWC
Spectrum Wealth Counsel
Indiana
-$2.28K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$2.85M – – –
RI
2
RTW Investments
New York
$2.38M -$553K -150,881 -16%
Marshall Wace
3
Marshall Wace
United Kingdom
$1.42M – – –
SC
4
Sessa Capital
New York
$1.42M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$857K +$367K +100,002 +57%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$184K -$14.9K -4,051 -6%
Millennium Management
7
Millennium Management
New York
$164K -$4.64K -1,266 -2%
Pathstone Holdings
8
Pathstone Holdings
New Jersey
$157K – – –
First Manhattan
9
First Manhattan
New York
$76.2K – – –
FPB
10
First PREMIER Bank
South Dakota
$60K +$71.1K +19,386 New
IFAM
11
Institutional & Family Asset Management
Colorado
$59.5K – – –
BlackRock
12
BlackRock
New York
$42.6K +$27.2K +7,413 +117%
Osaic Holdings
13
Osaic Holdings
Arizona
$14.1K +$37 +10 +0.2%
TRCT
14
Tower Research Capital (TRC)
New York
$7.42K +$3.51K +957 +67%
Morgan Stanley
15
Morgan Stanley
New York
$2.17K -$1.83K -500 -42%
PGAM
16
Princeton Global Asset Management
New Jersey
$1.55K – – –
GI
17
GS Investments
Minnesota
$620 – – –
Bank of America
18
Bank of America
North Carolina
$511 +$605 +165 New
JP Morgan Chase
19
JP Morgan Chase
New York
$329 +$7 +2 +2%
HI
20
Harbour Investments
Wisconsin
$155 – – –
Qube Research & Technologies (QRT)
21
Qube Research & Technologies (QRT)
United Kingdom
$19 – – –
CC
22
Commodore Capital
New York
– -$832K -183,174 Closed
SWC
23
Spectrum Wealth Counsel
Indiana
– -$2.28K -503 Closed
Wells Fargo
24
Wells Fargo
California
– -$277 -61 Closed
NA
25
NewEdge Advisors
Louisiana
– -$64 -14 Closed

SABS Hedge Fund Activity: Q2 2024 in Review

22 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2024, worth a combined $9.69M — down 36% from $15.2M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of SABS and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was Vanguard Group, adding an estimated $367K. The largest seller was Commodore Capital, exiting entirely with an estimated $832K sold.

  • 22 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2024, down from 24 in Q1 2024.
  • Funds reported $9.69M of SAB Biotherapeutics stock for Q2 2024, down 36% quarter-over-quarter.
  • 2 funds opened new SAB Biotherapeutics positions in Q2 2024 and 4 closed out, a net change of -2 holders.
  • The largest SAB Biotherapeutics buyer in Q2 2024 was Vanguard Group, an estimated $367K added.
  • The largest SAB Biotherapeutics seller in Q2 2024 was Commodore Capital, an estimated $832K sold.

Based on aggregated 13F filings for Q2 2024.